MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 16, 2005--Depomed, Inc. (Nasdaq:DEPO) announced today that it has filed a complaint in California Superior Court for San Mateo County against Biovail Corporation and its subsidiary, Biovail Laboratories International, relating to Biovail’s breaches of the parties’ 2002 license agreement, as amended, for Glumetza(TM), a once-daily extended release formulation of metformin approved for the treatment of Type II diabetes. The complaint asserts breach of contract and related claims, and seeks damages and a declaration that Depomed is entitled to terminate the contract as a result of Biovail’s breaches of the agreement.
